Twin-Twin Transfusion Syndrome at 18 Weeks: Laser vs Expectant Management
A 32-year-old G2P1 with a monochorionic diamniotic twin pregnancy presents at 18 weeks 0 days. Ultrasound shows a single placenta, a thin dividing membrane, and male fetuses. The recipient twin has a maximum vertical pocket (MVP) of 10.2 cm and a distended bladder; the donor twin has an MVP of 1.4 cm and an absent bladder. The donor's umbilical artery Doppler shows absent end-diastolic flow. The recipient has mild tricuspid regurgitation and a cardiothoracic ratio of 0.55. Cervical length is 32 mm. The patient is asymptomatic. She asks about the options and wants to know which gives the best chance for both babies.
1. What is the diagnosis and Quintero stage, and what does the staging imply for management?
Read the worked answer
The findings meet criteria for twin-twin transfusion syndrome (TTTS): monochorionic diamniotic pregnancy with polyhydramnios (MVP >8 cm) in one sac and oligohydramnios (MVP <2 cm) in the other. Quintero stage: stage I is poly/oligo only; stage II includes absent bladder in the donor; stage III includes critically abnormal Doppler (absent/reversed end-diastolic flow in the umbilical artery, reverse flow in the ductus venosus, or pulsatile umbilical vein); stage IV is hydrops; stage V is demise. This case has absent bladder (stage II) and absent end-diastolic flow in the donor umbilical artery (stage III), so it is Quintero stage III. Stage III TTTS is generally an indication for fetal intervention, typically selective fetoscopic laser photocoagulation, because expectant management carries high perinatal mortality and neurologic morbidity. The judgment is that the abnormal Doppler elevates the case to a stage where intervention is favored.
2. Compare selective fetoscopic laser photocoagulation with expectant management and with serial amnioreduction for this patient.
Read the worked answer
Selective laser photocoagulation of placental anastomoses is the first-line treatment for TTTS, especially stage II or higher, and is associated with improved survival of at least one twin and reduced neurologic morbidity compared with amnioreduction. Expectant management in stage III has high rates of fetal demise and preterm delivery. Amnioreduction treats polyhydramnios symptomatically but does not address the underlying anastomoses and has higher rates of recurrence and neurologic impairment. The choice depends on gestational age, access to a fetal surgery center, and the family's values. At 18 weeks, laser is technically feasible and generally preferred. Counseling should include risks: preterm premature rupture of membranes, preterm labor, and the possibility of losing one or both twins. The judgment is that laser offers the best chance for dual survival in stage III, but the family must accept procedure-related risks.
3. What preoperative and postoperative considerations would you counsel regarding laser surgery?
Read the worked answer
Preoperative: confirm monochorionicity and stage; assess cervical length (32 mm is reassuring, but short cervix may prompt cerclage or progesterone); arrange anesthesia (usually local or regional); discuss the risk of preterm premature rupture of membranes (reported around 10-20%) and preterm delivery. Intraoperative: map the placental anastomoses and the vascular equator; the goal is to coagulate all anastomoses. Postoperative: monitor for recurrence of TTTS, twin anemia-polycythemia sequence (TAPS), and fetal demise; serial ultrasounds and Dopplers. The patient should be counseled that even after successful laser, one twin may die, and that survival with neurologic impairment remains possible. The judgment is balancing the high risk of untreated stage III TTTS against procedure-related risks.